Hhlr Advisors, Ltd. Fibrogen Inc Transaction History

Hhlr Advisors, Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$10.18 - $26.64 $40.3 Million - $105 Million	-3,955,787 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $15.6 Million - $21.7 Million	452,500 Added 12.92%	3,955,787 $170 Million
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $28.8 Million - $37.7 Million	778,768 Added 28.58%	3,503,287 $130 Million
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $25.3 Million - $40.1 Million	721,232 Added 36.0%	2,724,519 $123 Million
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $76.1 Million - $121 Million	2,003,287 New	2,003,287 $92.7 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.